Mounjaro vs. Wegovy: The 2026 Guide for Asian Bodies & Thai Patients

Introduction: Why "Western" Weight Loss Rules Don't Apply to Us

If you are researching weight loss injections in 2026, you have likely heard of Wegovy (semaglutide) and the newer, more potent Mounjaro (tirzepatide). But most information online is based on Western bodies.

Asian genetics are different.

In Thailand, we often see patients with a "Skinny Fat" profile — normal body weight but high visceral fat (hidden belly fat) and metabolic risks. This condition requires a specific medical approach.

In our own clinic database, roughly one in three Thai patients seeking weight management present with this profile — normal BMI on paper, but elevated waist circumference and a body composition scan showing visceral fat above the healthy threshold. The published trial figures we cite below match the broad strokes of what we see, but each individual response varies, which is why we measure body composition before and during treatment rather than relying on the scale alone.

So, which injection is better for the Asian body type? Is it the clinically proven Wegovy, or the dual-action Mounjaro? Let's look at the data.

1. The "Thai" Proof: Why Wegovy is the Safe Bet

If you prioritize safety and local evidence, Wegovy is the gold standard. Unlike many drugs tested only in the US or Europe, Wegovy has a specific clinical trial relevant to us: the STEP 11 trial. ¹

• The study: Conducted specifically in Thailand and South Korea. 44-week phase 3 trial across 12 sites, BMI ≥ 25 kg/m² (Trial registration: NCT04998136).

• The result: Asian participants lost an average of 13.2% to 16% of their body weight.

• Why choose it: You have the confidence of knowing this drug was tested on our genetics, our diets, and our lifestyle. It is proven to work for Thai patients.

2. The "Metabolic Powerhouse": Why Mounjaro Wins on Potency

Mounjaro (tirzepatide) represents the next generation. It is the first "dual agonist," targeting two hormones (GLP-1 + GIP) instead of just one.

• The Asian data: While not tested in Thailand yet, Mounjaro has results from China (SURMOUNT-CN) and Japan (SURMOUNT-J).

• The result: In the Chinese trial, patients lost significantly more weight on tirzepatide 15 mg compared to placebo: 17.5% body weight reduction at 52 weeks. ²

• Best for "Skinny Fat": The added GIP hormone specifically improves how your body processes sugar and fat. This makes Mounjaro superior for reducing visceral fat — the dangerous "hidden" fat around your organs that is common in Asian genetics.

3. Side-by-Side Comparison: Asian Context

4. Price in Thailand (2026 Estimates)

Note: Prices vary by clinic and dosage; figures below reflect Thai market estimates as of April 2026.

• Wegovy: ฿14,000–฿23,000 per month (depending on dose).

• Mounjaro: ฿18,000–฿30,000+ per month.

Doctor's tip: Because Asian bodies are often more sensitive to these medications, many Thai patients see excellent results on lower doses of Mounjaro (5 mg or 7.5 mg), which can keep the monthly cost manageable compared to the maximum dose of Wegovy.

5. The "Ozempic Face" Concern

A major concern in Thailand is facial volume loss. Losing weight too fast can make you look older.

• The risk: Both drugs can cause this if dosed too aggressively.

• The solution: We use a "slow titration" protocol. By increasing the dose slowly, we protect your facial structure while slimming your waistline. We can also combine treatment with biostimulators to maintain collagen.

Conclusion: Which One Should You Choose?

• Choose Wegovy if: You are conservative. You want the drug that was explicitly tested in Thailand (STEP 11) and has a long safety record.

• Choose Mounjaro if: You have insulin resistance, high visceral fat, or have "stalled" on other diets. Its dual-action mechanism attacks the metabolic root cause of "Skinny Fat" more effectively than any other drug on the market.

Ready to transform your metabolic health? Consult with Dr. Akkavich at Phuket Weight Loss Center to find the right dosage for your specific genetic profile.

References

• Lim S, Sohn M, Cho YM, et al. Once-weekly semaglutide 2.4 mg in an Asian population with obesity (STEP 11). Lancet Diabetes Endocrinol. 2025. Trial registration: NCT04998136.

• Zhao L, Cheng Z, Lu Y, et al. Tirzepatide for weight reduction in Chinese adults with obesity (SURMOUNT-CN). JAMA. 2024;332(7):551-560.

• WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-163.

Medically reviewed
Siam Clinic Medical Team
The medical information published on this website has been reviewed by the Siam Clinic medical team and draws on reliable medical sources, including research and peer-reviewed academic articles.

We place great importance on accuracy, clarity and appropriate presentation, so that readers can use this information to make well-informed decisions about their health.